Patent intelligence · US
US 11364300
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
Patent details — US 11364300
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 21, 2022
- Expiration
- Jun 16, 2042
- Applicant
- Revolution Medicines, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/436, A61K31/519, A61K31/553
Quick answer
US 11364300 (C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/436, A61K31/519, A61K31/553, A61K47/545, A61P
More from Revolution Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12409225
Ras inhibitors
granted -
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted
Frequently asked questions
What is US patent 11364300?
US 11364300 (C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors) is held by Revolution Medicines, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11364300?
Revolution Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 11364300 expire?
Our index shows an expiration date of Jun 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.